MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ('MIRA' or the 'Company'), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation.
Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects.
'These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential,' said Erez Aminov, Chairman and CEO of MIRA. 'We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain.'
Study Overview and Key Findings
Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume.
Key findings:
Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline levels.
Its analgesic effect was equivalent to morphine, the standard opioid comparator in the study.
No sedation or inflammatory swelling was observed with Mira-55 treatment.
Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development.
These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile.
'Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs,' said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. 'Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards.'
Strategic Fit Within MIRA's Pain Portfolio
Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain.
'With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated,' added Aminov. 'We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline.'
Corporate Update on SKNY Merger
MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction.
'We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation,' said Aminov. 'This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth.'
Next Steps
MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
How to Access Your Texas Roadhouse Paystubs Online (2025 Guide)
If you're a Texas Roadhouse employee, keeping track of your paystubs is essential—whether you're budgeting, filing taxes, or simply double-checking your hours and deductions. Thankfully, accessing your paystubs online is quick and easy if you know where to go. In this guide, we'll walk you through exactly how to find and view your Texas Roadhouse paystubs online, using tools provided by the company and with the help of go-to portal for all employee login needs. A paystub (also known as a paycheck stub) is a document that outlines your earnings, tax withholdings, and other deductions for a given pay period. It's your record of how much you've earned and what's been withheld. Paystubs are important for: Verifying your income Tracking your hours and overtime Confirming benefit deductions Filing taxes accurately Resolving paycheck discrepancies To access your paystub online, follow these simple steps: This website is designed specifically to help Texas Roadhouse employees access work-related services like: Paystubs W-2s Workday login Payroll support Go to the homepage and click the relevant login link for either Workday or the employee portal. You'll need your: Username or employee ID Password (If prompted) Two-step verification code 💡 Tip: If you've forgotten your credentials, provides troubleshooting help and links to reset your password or recover your account. Once logged in: Look for the 'Pay' , 'Compensation' , or 'Earnings' tab , , or tab Click on the most recent pay period or the date range you want to view Your paystub will show: Gross and net pay Hours worked Overtime Federal, state, and local taxes Benefits deductions Year-to-date totals You can download a PDF version for your records or print it directly if needed for loan applications, rentals, or tax filing. Texas Roadhouse typically pays employees weekly, and your paystub is updated at the end of each pay cycle (usually on Thursdays or Fridays). If you're not seeing your latest paystub, wait 24–48 hours and check again. If you're having issues: Double-check your login credentials Clear your browser cache or try a different browser Use a desktop instead of a phone for more reliable access Still stuck? Visit for: Direct links to Texas Roadhouse portals Password reset help Step-by-step login troubleshooting Save each paystub in a folder (digital or physical) in a folder (digital or physical) Check for errors in hours or deductions regularly in hours or deductions regularly Download year-end summaries for tax filing ease for tax filing ease If you leave the company, download your final paystub before access ends Whether you're accessing your paystub, W-2, or logging into Workday, has everything you need to manage your employment details with Texas Roadhouse. ! TIME BUSINESS NEWS
Yahoo
2 hours ago
- Yahoo
The Lovesac Company's (NASDAQ:LOVE) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Lovesac (NASDAQ:LOVE) has had a great run on the share market with its stock up by a significant 34% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. Specifically, we decided to study Lovesac's ROE in this article. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Lovesac is: 6.8% = US$14m ÷ US$201m (Based on the trailing twelve months to May 2025). The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.07. View our latest analysis for Lovesac We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. At first glance, Lovesac's ROE doesn't look very promising. Next, when compared to the average industry ROE of 15%, the company's ROE leaves us feeling even less enthusiastic. As a result, Lovesac reported a very low income growth of 4.0% over the past five years. As a next step, we compared Lovesac's net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 11% in the same period. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is LOVE fairly valued? This infographic on the company's intrinsic value has everything you need to know. Lovesac doesn't pay any regular dividends, meaning that potentially all of its profits are being reinvested in the business. However, this doesn't explain the low earnings growth the company has seen. So there could be some other explanation in that regard. For instance, the company's business may be deteriorating. Overall, we have mixed feelings about Lovesac. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $359.72 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Niu Technologies Provides Second Quarter 2025 Sales Volume Update
BEIJING, July 04, 2025 (GLOBE NEWSWIRE) -- Niu Technologies ('NIU', or 'the Company') (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume results for the second quarter of 2025. 2Q 2025 2Q 2024 1H 2025 1H 2024 China Market 318,719 207,552 501,784 317,667 International Markets 31,371 48,610 51,619 67,634 Total 350,090 256,162 553,403 385,301 In the second quarter of 2025, NIU sold 350,090 units, including e-motorcycles, e-mopeds, e-bicycles, kick-scooters and e-bikes. Sales in the China and international markets were 318,719 and 31,371 units, respectively. In China, we remained focused on our key product line development strategy, enhancing existing models through continuous upgrades and refining our product portfolio. These efforts resulted in an optimized product mix that appeals to a broader range of consumers and delivers a more enjoyable riding experience. During the '618 Shopping Festival,' our high-end models secured top rankings across major e-commerce platforms, including Tmall, JD and Douyin. This strong performance further solidifies NIU's position in China's premium market, appealing to riders who value design and innovation. In the international markets, we launched a comprehensive portfolio of electric motorcycles, including off-road models. Supported by an expanded distribution network, this lineup has significantly strengthened our global market position, despite ongoing challenges in the micromobility sector due to a complex and uncertain environment. Our sales volume count disclosed above is based on the delivery from our manufacturing facility, which may vary slightly from the sales volume measured from a financial accounting and reporting point of view. NIU's sales volume represents only one measure of the company's financial performance and should not be relied upon as an indicator of quarterly financial results, which depend on a variety of factors, including revenues from accessories, spare parts and services, cost of sales, operating expenses, etc. About NIU As the world's leading provider of smart urban mobility solutions, NIU designs, manufactures and sells high-performance electric motorcycles, mopeds, bicycles, as well as kick-scooters and e-bikes. NIU has a diversified product portfolio that caters to the various demands of our users and addresses different urban travel scenarios. Currently, NIU offers two model lineups, comprising a number of different vehicle types. These include (i) the electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, FQi series and others, and (ii) the micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. NIU has adopted an omnichannel retail model, integrating the offline and online channels, to sell its products and provide services to users. For more information, please visit Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'likely to' and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as NIU's strategic and operational plans, contain forward-looking statements. NIU may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIU's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIU's strategies; NIU's future business development, financial condition and results of operations; NIU's ability to maintain and enhance its 'NIU' brand; its ability to innovate and successfully launch new products and services; its ability to maintain and expand its offline distribution network; its ability to satisfy the mandated safety standards relating to e-scooters; its ability to secure supply of components and raw materials used in e-scooters; its ability to manufacture, launch and sell smart e-scooters meeting customer expectations; its ability to grow collaboration with operation partners; its ability to control costs associated with its operations; general economic and business conditions in China and globally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIU's filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and NIU does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Niu TechnologiesE-mail: ir@ in to access your portfolio
